Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure

1 Feb 1999

Abstract excerpt

T22, an analog of polyphemusin II (18 amino acid residues), was found to block T-tropic human immunodeficiency virus type 1 (HIV-1) entry into target cells as a CXCR4 inhibitor. We synthesized T134, a small analog (14 amino acid residues) of T22 with reduced positive charges. T134 exhibited highly potent activity and significantly less cytotoxicity in comparison to that of T22. T134 prevents the anti-CXCR4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine receptors and signaling
Share to HIV Research and Treatment
Share to interferon and immune responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9882387
DOI: 10.1128/jvi.73.2.1719-1723.1999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different StructurePMID 9882387Read ↗

Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.Semantic proximity Read ↗

CXCR4 Is a Potential Target for Anti-HIV Gene TherapySemantic proximity Read ↗

Development of N-terminally modified variants of the CXCR4-antagonizing peptide EPI-X4 with increased plasma stabilitySemantic proximity Read ↗

Biomolecular models of EPI-X4 binding to CXCR4 allow the rational optimization of peptides with therapeutic potentialSemantic proximity Read ↗

Designing small molecule CXCR3 antagonistsSemantic proximity Read ↗

Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.Semantic proximity Read ↗

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsSemantic proximity Read ↗

Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.Semantic proximity Read ↗

Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virusSemantic proximity Read ↗

Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonistsSemantic proximity Read ↗

Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211.Semantic proximity Read ↗

A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.